Eli Lilly and Company - Asset Resilience Ratio
Eli Lilly and Company (LLY) has an Asset Resilience Ratio of 8.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Eli Lilly and Company (LLY) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. See LLY net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LLY company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $9.79 Billion | 8.52% |
| Short-term Investments | $121.60 Million | 0.11% |
| Total Liquid Assets | $9.91 Billion | 8.63% |
Asset Resilience Insights
- Limited Liquidity: Eli Lilly and Company maintains only 8.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Eli Lilly and Company Industry Peers by Asset Resilience Ratio
Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Eli Lilly and Company (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.35% | $3.42 Billion | $78.71 Billion | -0.23pp |
| 2023-12-31 | 4.57% | $2.93 Billion | $64.01 Billion | +0.10pp |
| 2022-12-31 | 4.47% | $2.21 Billion | $49.49 Billion | -3.54pp |
| 2021-12-31 | 8.01% | $3.91 Billion | $48.81 Billion | +0.11pp |
| 2020-12-31 | 7.89% | $3.68 Billion | $46.63 Billion | +1.69pp |
| 2019-12-31 | 6.21% | $2.44 Billion | $39.29 Billion | -10.67pp |
| 2018-12-31 | 16.87% | $7.41 Billion | $43.91 Billion | -0.99pp |
| 2017-12-31 | 17.86% | $8.03 Billion | $44.98 Billion | +2.30pp |
| 2016-12-31 | 15.56% | $6.04 Billion | $38.81 Billion | +13.35pp |
| 2015-12-31 | 2.21% | $785.40 Million | $35.57 Billion | -0.42pp |
| 2014-12-31 | 2.63% | $955.40 Million | $36.31 Billion | -1.81pp |
| 2013-12-31 | 4.45% | $1.57 Billion | $35.25 Billion | -0.40pp |
| 2012-12-31 | 4.84% | $1.67 Billion | $34.40 Billion | +1.95pp |
| 2011-12-31 | 2.90% | $974.60 Million | $33.66 Billion | +0.53pp |
| 2010-12-31 | 2.37% | $733.80 Million | $31.00 Billion | +2.24pp |
| 2009-12-31 | 0.13% | $34.70 Million | $27.46 Billion | -1.34pp |
| 2008-12-31 | 1.47% | $429.40 Million | $29.21 Billion | -4.54pp |
| 2007-12-31 | 6.01% | $1.61 Billion | $26.79 Billion | +2.45pp |
| 2006-12-31 | 3.56% | $781.70 Million | $21.96 Billion | -4.70pp |
| 2005-12-31 | 8.26% | $2.03 Billion | $24.58 Billion | -0.18pp |
| 2004-12-31 | 8.44% | $2.10 Billion | $24.87 Billion | +4.03pp |
| 2003-12-31 | 4.41% | $957.00 Million | $21.68 Billion | -4.56pp |
| 2002-12-31 | 8.97% | $1.71 Billion | $19.04 Billion | +2.71pp |
| 2001-12-31 | 6.26% | $1.03 Billion | $16.43 Billion | +2.83pp |
| 2000-12-31 | 3.43% | $503.30 Million | $14.69 Billion | +2.37pp |
| 1999-12-31 | 1.06% | $135.60 Million | $12.83 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardi… Read more